Our view

Selective with patent and research risks priced in. Legacy franchises can fund a transition, but replacement sales must arrive before major exclusivity losses. Business-development spending should be assessed against cash returns rather than deal volume.

What the financial disclosures show

Revenue was 16.583 billion USD, compared with 16.654 billion USD on the comparison basis in the table. The reporting basis is Quarter ended 2026-09-27 vs 2025-09-28.

What to monitor over several reporting periods

Track new-product growth, concentration, leverage and dividend coverage after required investment.

Risks to account for in the entry price

Patent erosion, uncertain vaccine recommendations and seasonal COVID demand can offset commercial progress elsewhere.

Acquisition execution, development failures, price pressure and leverage can limit room for mistakes in the replacement strategy.

What would change the long-term view

If pipeline or acquired products cannot replace mature cash earnings, a low reported multiple can be misleading.

Data and assumptions

Dated evidence from financial filings and issuer releases
Ticker Metric Reported or derived value Comparator Period or basis Source
PFE Revenue 16.583 billion USD 16.654 billion USD Quarter ended 2026-09-27 vs 2025-09-28 Filing
PFE Net income attributable to parent 3.242 billion USD 3.541 billion USD Quarter ended 2026-09-27 vs 2025-09-28 Filing
PFE GAAP diluted EPS 0.56 USD/shares 0.62 USD/shares Quarter ended 2026-09-27 vs 2025-09-28 Filing
PFE Cash and cash equivalents at period end 1.824 billion USD 1.343 billion USD 2026-09-27 balance vs 2025-09-28 Filing

Reporting dates, units and definitions appear with each observation.

Frequently asked questions

What evidence should PFE investors follow over time?

Track new-product growth, concentration, leverage and dividend coverage after required investment.

Does the report period establish a fair entry price for PFE?

The disclosure provides the operating baseline. For an entry price, build a normalized per-share earnings or cash-flow case and compare the price with a downside scenario for the driver identified above.

Related research

Is Pfizer Stock Worth Buying Now?

Discuss the research

Use the existing WhatsApp group button to discuss the evidence and compare your assumptions.

Sources

Educational research. Investment values and income can decline. Scenario inputs are illustrative.